Drug Fix: US FDA’s Peptide Drama, More Transparency, Ibogaine Clinical Trial Plans
Freitag, 9. Oktober 2026 · 41 min
Kapitelklicken springt direkt hin
Shownotes
Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Senior Editor Sue Sutter and Senior Reporter Maaisha Osman discuss the drama unfolding at the US Food and Drug Administration related to a Health and Human Services Department plan to temporarily allow some compounding of unapproved peptides (:52).
They also consider the impact of the FDA’s intent to acknowledge individual NDA and BLA filings () and whether the policy will have to endure legal challenges (), as well as the potential clinical trial requirements for the psychedelic ibogaine and their potential impact on product development ().
More On These Topics From The Pink Sheet
US FDA Staff Push Back Against Trump Administration Interim Peptide Dispensing Order: insights.citeline.com/pink-sheet/product-revie…
Transparency Growing: US FDA Plans Reg Allowing NDA, BLA Filing Disclosure: insights.citeline.com/pink-sheet/pathways-and-…
US FDA Signals Cardiac Safety Monitoring Will Be Ibogaine’s Regulatory Hurdle: insights.citeline.com/pink-sheet/r-and-d/clini…
